About

The Afimmune management team has both a strong background in developing drugs for the market and experience in building life science companies.

Pipeline

Afimmune has assets in various stages of clinical and pre-clinical development.

Investors

To date, Afimmune has been funded privately.

Latest News

September 19, 2024
Published by Melanie Hurley Iveagh at September 19, 2024
Categories

Epeleuton for Sickle Cell Disease receives key US patent grant

Dublin, Ireland, 18th September 2024 – Afimmune, a clinical stage drug discovery and development company, today announced that the U.S. Patent and Trademark Office has issued […]
Do you like it?0
Read more
April 19, 2024
Published by Melanie Hurley Iveagh at April 19, 2024
Categories

Afimmune Announces Partnership in Sickle Cell Disease Research with Pathway to Cures

Dublin, Ireland, 19 April 2024: Afimmune announced today its collaborative partnership with Pathway to Cures (P2C) to support the development of Epeleuton as a potential therapeutic […]
Do you like it?0
Read more

More Press Releases

Join our mailing list

Connect with us

Contact us

t: +353 1 2933 590
e: [email protected]